

TABLE OF CONTENTS

June 8, 2009

No. 2142

BUSINESS

- 1 NBI's Sales Exceeded Industry Average for Five Consecutive Years: Dr T. Heil
 - Micombi, Spiriva to Bolster Business
 - Application for Dabigatran Expected in 2010
- 3 Takeda Licenses Hib Vaccine from Novartis
- 3 Daiichi Sankyo Revises Net Loss from ¥335.8 Bil. to ¥215.5 Bil.
- 4 Co-DIO, Ecard Ranked No. 1 and 2 on Both GP and HP Markets
- 4 Yoshiki Bessho of Suzuken Elected New FJPWA President
- 6 CMIC: Semi-Annual Sales Up 14.4% Driven by CRO Business
 - Negotiating Marketing Rights for Normosang
 - CMIC Ties Up with PHT Corp. for ePRO
- 6 EPS: Strong CRO Business Pushes Up Sales 11.6%
 - EPS Hong Kong Opened
- 7 **BUSINESS NEWS IN BRIEF**
 - NanoCarrier Licenses Nucleic Acid Technology from Todai
 - Suzuken to Acquire Drug Freighter/Distributor
 - Sanofi-aventis to Produce MABs in France
 - Takara Bio: Sales Down 6.7%; Aiming at ¥20 Bil. Sales in FY2011

REGULATORY

- 8 Initiate Policies that Attract R&D: PhRMA Chairman D. Brennan
- 8 *Chuikyo* Subcommittee to Review Whether Price Gaps Promote Use of Generics
 - New Rule Needed Assuming that Bulk Buying will Persist: Prof. Endo
 - New Market Price Survey to Be Conducted in FY2009
 - Increases in Frequency of NHI Price Revisions Not Supported by Any Member
- 10 *Ryukaikon* Reviews One Year of Efforts to Improve Distribution Business Practices
 - Low Price Settlement Rates for Public Hospitals
 - Wholesalers Must Stop Placing Top Priority on Sales: Mr Matsutani
 - Makers and Wholesalers Should Discuss on Equal Footing: Mr Negi
 - No Further Improvements Can Be Expected if Latecomers Continue to Be Better Served: Dr Koyama
- 10 Otsuka: Hyponatremia Drug Approved in the US
- 11 **REGULATORY NEWS IN BRIEF**
 - HCC Approved as Additional Indication for Nexavar
 - Cimzia Approved for RA in US: UCB
 - Metformin Approved for Use in First-Line Therapy
 - Controlled-Release Formulation of Carmustine Recommended as Orphan Drug

GENERICS

- 13 Sawai: Sales, Profits Up Driven by Gov't Policy to Promote Use of Generics
 - Aiming at ¥100 Bil. Sales in 5 Years

- 13 Towa: New Products Listed in 2008 Drive Sales
 - Building Up Its Own Distribution Route in Hospital Market
 - Direct Deal Started with Rosai Hospitals
 - New Plant in Yamagata
- 14 Nichi-Iko to Create Joint Venture with Mitani Sangyo to Manufacture Raw Materials for Generics
- 15 *Koroshio* to Call For Stricter Adherence to Ryotankisoku for Use of More Generics
 - More Generic Substitution Needed: *Chuikyo* Committee
 - *Koroshio* to Present Data on Use of Generics at Individual Univ. Hospitals
- 16 **Commentary**
 - JSHP to Promote Use of Generics

SELF-MEDICATION

- 17 Rohto: Sales Up 16th Year in a Row
 - T. Yoshino to Be Promoted to President
- 17 Taisho Launches RiUP X5 Hair Growth Stimulator for Men
- 17 Switch OTC Drugs Based on Vidarabine Recommended for Approval
- 18 Council on Online Sale of OTC Drugs Fails to Reach a Consensus
 - *Koroshio* to Introduce Proposed Provisional Measures Anyway
 - Most Council Members against Proposed Provisional Measures
- 19 Kenko.com, Wellnet Sue *Koroshio* Claiming that Ministerial Ordinance Goes against Law

MEDICAL DEVICES

- 19 Schedule for Medical Materials System Reform Approved

R&D

- 20 Encouraging Results Obtained with Lurasidone in PIII Trial: DSP
- 21 **R&D NEWS IN BRIEF**
 - GLP-1, DPP-4 Drugs More Effective in Japanese
 - Bayer to Initiate Multinational PIII Program for VEGF Trap-Eye Including Japan

ON THE MOVE

- 20 - Atul Sobti Named CEO of Ranbaxy

MEDICAL FACILITIES & NURSING CARE

- 21 Sleep Disorders Increase Risk of Other Diseases
- 22 Only 20% of Mothers Talk to Daughters about GYN Diseases
- 22 Publicity on RLS Essential for Patients, Physicians
- 23 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - Fax Allowed to Be Used to Prescribe Anti-viral Agents
 - New-Type Flu Virus Infections Compromise Supply of Blood Products
 - Tamiflu Sold at High Prices Via Internet